<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>As many as 450 countrymen 20 to 59 years old were examined </plain></SENT>
<SENT sid="1" pm="."><plain>They underwent the following measurements: concentration of total <z:chebi fb="0" ids="16113">cholesterin</z:chebi>, <z:chebi fb="4" ids="17855">triglycerides</z:chebi>, cholesterol of high-, low- and very low dencity <z:chebi fb="2" ids="6495">lipoproteins</z:chebi>; there has also been studied the incidence of dyslipoproteinemias </plain></SENT>
<SENT sid="2" pm="."><plain>The prevalence of atherogenic and antiatherogenic dyslipoproteinemias is as follows: 8.3 % (type II a), 1.6 % (type 11 b), 0.2 % (type III), 7.4 % (type IV), 1.1 % (type V) 11 % (<z:e sem="disease" ids="C0342883" disease_type="Disease or Syndrome" abbrv="">hyperalphalipoproteinemia</z:e>), 3.6 % (<z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e>), and 6.1 % (<z:hpo ids='HP_0003563'>hypobetalipoproteinemia</z:hpo>), as evidenced by phenotyping studies </plain></SENT>
<SENT sid="3" pm="."><plain>A substantial proportion of examenees (59.5 %) are those individuals with normolipoproteinemia </plain></SENT>
</text></document>